COVID-19 AND PATIENTS UNDERGOING PHARMACOLOGICAL TREATMENTS FOR IMMUNE-MEDIATED INFLAMMATORY DISEASES: PROTOCOL FOR A RAPID LIVING SYSTEMATIC REVIEW

• Autor(a) principal: Puga, Maria Eduarda dos Santos
• Data de Publicação: 2020
• Outros Autores: Rocha, Aline Pereira da, Atallah, Alvaro Nagib, Pinto, Ana Carolina Pereira Nunes, Rocha-Filho, César Ramos, Reis, Felipe Sebastião de Assis, Milby, Keilla Martins, Civile, Vinicius Tassoni, Carvas Junior, Nelson, Santos, Rodolfo Rodrigo Pereira, Ferla, Laura Jantsch, Trevisani, Giulia Fernandes Moça, Ramalho, Gabriel Sodré, Trevisani, Virgínia Fernandes Moça
• Tipo de documento: preprint
• Idioma: eng
• Título da fonte: SciELO Preprints
• Texto Completo: https://preprints.scielo.org/index.php/scielo/preprint/view/349
• topic: Immune-mediated diseases; living systematic review; COVID-19

CONTEXT AND OBJECTIVE: We propose to systematically review the available evidence to evaluate if patients with immune mediated or inflammatory diseases under pharmacological treatment with immunosuppressants, immunobiologics, DMARDs or targeted synthetic DMARDs have better or worse outcomes when infected by SARS-CoV-2. This study is a protocol for our rapid living systematic review. METHODS: Protocol for a rapid living systematic review methodology following the preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) guidance. To conduct the rapid systematic review, we will employ abbreviated systematic review methods, including: not performing independent screens of abstracts and not searching grey literature. As this will be a living review, it will be continuously updated.